Last reviewed · How we verify
Vitamin D3 cholecalciferol)
Vitamin D3 (cholecalciferol), marketed by the Abramson Cancer Center at Penn Medicine, serves as a homeo-nutritional support for bone health. A key strength is the protection provided by a composition patent expiring in 2028. The primary risk is the lack of significant revenue data, which may impact market valuation and investment interest.
At a glance
| Generic name | Vitamin D3 cholecalciferol) |
|---|---|
| Also known as | Natures Made Vitamin D3, Cholecalciferol, Vitamin D3, Placebo, inert white powder, Vitamin D3 Matching Placebo |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Drug class | Vitamin D [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Homeo-nutritional support of bones
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vitamin D3 cholecalciferol) CI brief — competitive landscape report
- Vitamin D3 cholecalciferol) updates RSS · CI watch RSS
- Abramson Cancer Center at Penn Medicine portfolio CI